title: Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.
abstract: Diverticular disease is a common bowel condition, the pathogenesis of which is incompletely understood. Acute exacerbations of diverticular disease usually require dietary changes, antibiotic therapy, and may necessitate urgent surgery. Approximately 25-33% of patients experience symptomatic and acute inflammatory disease recurrence, suggesting that current long-term management is inadequate. Because inflammatory complications of diverticular disease, including diverticulitis, are similarities to inflammatory bowel diseases, evidence suggests that patients may respond to anti-inflammatory therapies used in these conditions. Here, we explore the rationale and evidence for use of inflammatory bowel disease treatment, namely 5-aminosalicylic acid (5-ASA; mesalamine), in diverticular disease, and review clinical data on the efficacy of mesalamine either alone or in combination with other agents for the treatment of diverticular disease. PubMed and conference abstracts were searched for clinical studies examining the use of mesalamine in treating diverticular disease. Studies were evaluated for treatment efficacy in symptom reduction, recurrence prevention, or improving quality of life. The results of our search suggest that single-agent mesalamine can reduce diverticular disease symptoms and improve quality of life more effectively than antibiotic treatment alone. Mesalamine in combination with antibiotics can also reduce symptoms and improve quality of life with greater efficacy than either treatment alone. Combining mesalamine and probiotics treatments may reduce recurrent attacks of diverticular disease. Further randomized, well-controlled studies are required for validation; however, it seems that mesalamine is an important agent in future diverticular disease management.
authors.affiliation: Gastroenterology Service, ASL BAT, Via Torino, 49, 76123 Andria, BT, Italy. antotursi@tiscali.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Tursi
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Joseph
authors.forename: Paul
authors.initials: P
authors.lastname: Streck
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004238:Diverticulitis / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D019936:Probiotics / Q000627:therapeutic use; D012074:Remission Induction; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D012294:Rifamycins; D019804:Mesalamine; D000078262:Rifaximin